Co-managing Director, SYNthesis BioVentures
| Role | Organisation | Sources |
|---|---|---|
| Co-managing Director | SYNthesis BioVentures | Synthesis BioVentures |
| Managing Director | SYNthesis BioVentures | Synthesis BioVentures (21 Oct 2024), Synthesis BioVentures (9 Apr 2024) |
Stories naming Amir Zalcenstein. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
Sydney biotech Skin2Neuron raised $4 million from SYNthesis BioVentures to develop a hair-follicle cell therapy for Alzheimer's, while the investor reached the first $20 million close of its $75 million bioscience fund.
Also SmartCompany
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.